TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20131255

Group type: EXPERIMENTAL
Intervention: Low-dose colchicine (1.8 mg total over 1 hour)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: High-dose colchicine (4.8 mg total over 6 hours)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Low-dose colchicine
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: High-dose colchicine
Number of subjects: 184
Study: 17175393

Group type: EXPERIMENTAL
Intervention: Parental control
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Parental warmth
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Parental limit setting and autonomy support
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nurturance and involvement
Number of subjects: 98
Study: 18082856

Group type: EXPERIMENTAL
Intervention: Vaginal contraceptive ring
Number of subjects: 130

Group type: COMPARATOR
Intervention: Oral contraceptive pills
Number of subjects: 130
Study: 15095939

Group type: EXPERIMENTAL
Intervention: External reference cues added when body-centered coding was disrupted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External reference cues added to intact body-centered reference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Body-centered reference disrupted by orienting the map differently
Number of subjects: 0
Study: 10965832

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 18

Group type: COMPARATOR
Intervention: Open tension‐free repair
Number of subjects: 18
Study: 9068513

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study: 8249222

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 2 weeks
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Minocycline for 2 weeks
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 143
Study: 2412262

Group type: EXPERIMENTAL
Intervention: Leucocyte interferon in daily doses of 3 x 10(6) I.U.i.m
Number of subjects: 20

Group type: COMPARATOR
Intervention: Irradiation of both lungs in a calculated mean central dose of 10 Gy in 4 weeks in combination with bleomycin and vincristine
Number of subjects: 20
Study: 11172448

Group type: EXPERIMENTAL
Intervention: Nutrition intervention tailored to patient-specific barriers (52 patients)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care (31 patients)
Number of subjects: 83
Study: 31283605

Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Number of subjects: 58

Group type: COMPARATOR
Intervention: 68Ga-PSMA-11
Number of subjects: 58
Study: 29554789

Group type: EXPERIMENTAL
Intervention: Instructional video on performance of vascular anastomosis using visualization
Number of subjects: 32

Group type: COMPARATOR
Intervention: Expert-guided simulator training alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 26833358

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral treatment (cART) started at a mean age of 8.1 months
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral treatment (cART)
Number of subjects: 68
Study: 24434783

Group type: EXPERIMENTAL
Intervention: Child intervention with massage and humor therapy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Child intervention with massage and relaxation/imagery
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 171
Study: 22845045

Group type: EXPERIMENTAL
Intervention: Two-compound ointment (calcipotriol 50 μg/g; betamethasone dipropionate 0.5 mg/g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Two-compound gel (calcipotriol 50 μg/g; betamethasone dipropionate 0.5 mg/g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 μg/g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcipotriol/hydrocortisone ointment (calcipotriol 25 μg/g; hydrocortisone 10 mg/g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 μg/g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 24
Study: 20803154

Group type: EXPERIMENTAL
Intervention: Fighting simulation (3 fights, 6 min each, 30 min rest between fights)
Number of subjects: 20
Study: 17608155

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medication only (antihistamines and intranasal corticosteroids)
Number of subjects: 30
Study: 15652441

Group type: EXPERIMENTAL
Intervention: OAD morphine (mean 238 +/- 319 mg q24h)
Number of subjects: 25

Group type: COMPARATOR
Intervention: twice-daily CR morphine (mean 119 +/- 159 mg q12h)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OAD morphine
Number of subjects: 25

Group type: COMPARATOR
Intervention: twice-daily CR morphine
Number of subjects: 25
Study: 12000207

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 491
Study: 10452766

Group type: EXPERIMENTAL
Intervention: Sublingual standardized Parietaria judaica extract (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 41
Study: 8552268

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg/die monotherapy
Number of subjects: 669

Group type: COMPARATOR
Intervention: Lisinopril 20 mg + Hydrochlorothiazide 12.5 mg/die combination
Number of subjects: 669
Study: 2201888

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol, Vita‐Glow)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 850011

Group type: EXPERIMENTAL
Intervention: Modeling
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Video Feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Role Playing
Number of subjects: 48

Group type: COMPARATOR
Intervention: No Treatment Control
Number of subjects: 48
Study: 30702630

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 45
Study: 29170074

Group type: EXPERIMENTAL
Intervention: IV antibiotics for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV antibiotics for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV antibiotics for 21 days
Number of subjects: 0
Study: 27473371

Group type: EXPERIMENTAL
Intervention: Complex intervention comprising educational training on HCV, poster and leaflet display, HCV risk prediction algorithm, and patient recall for testing.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 46
Study: 23096129

Group type: EXPERIMENTAL
Intervention: Surgical treatment of AIS (hybrid and pedicle screws alone)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Surgical treatment of AIS
Number of subjects: 33
Study: 22198675

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim on day + 1 (Peg1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pegfilgrastim on day + 4 (Peg4)
Number of subjects: 53
Study: 20074355

Group type: EXPERIMENTAL
Intervention: Coercion Experience Scale (CES)
Number of subjects: 102
Study: 17409368

Group type: COMPARATOR
Intervention: Physician using no decision support system (DSS)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Physician using unspecified DSS
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Physician using DSS from a prestigious medical center
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Physician heeding DSS recommendation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Physician defying DSS recommendation with less aggressive treatment
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Physician defying DSS recommendation with more aggressive treatment
Number of subjects: 205
Study: 16100184

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) at doses > 100 microg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14622682

Group type: EXPERIMENTAL
Intervention: Oral hydromorphone (8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil (0.10 microg.kg(‐1).min(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral lamotrigine (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10822390

Group type: EXPERIMENTAL
Intervention: Serum levels of PICP, OC, ICTP and urinary levels of Pyr and Dpyr in patients with OPLL
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (20 healthy males aged 45-78, mean age 63.0 +/- 11.5)
Number of subjects: 22
Study: 8896139

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment after cross-over from placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1855811

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 12
Study: 6350313

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) with citrovorum factor rescue (CFR) and cis-platinum
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Combination of adriamycin or bleomycin, cyclophosphamide, and dactinomycin (BCD)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with citrovorum factor rescue
Number of subjects: 189
Study: 31912155

Group type: EXPERIMENTAL
Intervention: Walnut diet (30-60 g/d, ∼15% energy)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Control diet (abstention from walnuts)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Walnut diet (Barcelona cohort)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Control diet (Barcelona cohort)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Brain fMRI (subset of Barcelona participants)
Number of subjects: 708
Study: 30630722

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (communication, systematic pain management, medication review, activities) with standardized education and on-site training for 4 months.
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 723

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 723
Study: 30153111

Group type: COMPARATOR
Intervention: Atenolol, 50 mg/day
Number of subjects: 155

Group type: COMPARATOR
Intervention: Nebivolol, 5 mg/day
Number of subjects: 155

Group type: COMPARATOR
Intervention: Propranolol, 20 mg b.i.d.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Propranolol, 40 mg b.i.d.
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 155
Study: 27291249

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg once daily and Ribavirin for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg once daily and Ribavirin for 24 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Grazoprevir plus Ribavirin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 26
Study: 24467247

Group type: EXPERIMENTAL
Intervention: Steam vapor treatment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Vacuuming
Number of subjects: 4

Group type: COMPARATOR
Intervention: Chemical method (benzalkonium chloride)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Physical methods (steam vapor and vacuuming)
Number of subjects: 4
Study: 22271410

Group type: EXPERIMENTAL
Intervention: Selective TACE targeting the tumor (selective group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Whole-liver TACE plus chemolipiodolization (whole-liver group)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no preoperative TACE or chemolipiodolization)
Number of subjects: 124
Study: 19782343

Group type: EXPERIMENTAL
Intervention: Multimodal cognitive-behavioral training (CBT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Educational intervention (EDU)
Number of subjects: 65

Group type: COMPARATOR
Intervention: CBT vs EDU
Number of subjects: 65

Group type: COMPARATOR
Intervention: AR vs EDU
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Follow-up assessment for CBT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Follow-up assessment for AR
Number of subjects: 65

Group type: COMPARATOR
Intervention: Follow-up assessment for EDU
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Overall effects across all groups
Number of subjects: 65
Study: 16545792

Group type: EXPERIMENTAL
Intervention: Orthographic properties of words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16014595

Group type: EXPERIMENTAL
Intervention: Structured interview identifying residents for hospice care
Number of subjects: 205
Study: 11880962

Group type: EXPERIMENTAL
Intervention: 3-day treatment with valacyclovir (500 mg twice daily)
Number of subjects: 800

Group type: COMPARATOR
Intervention: 5-day treatment with valacyclovir (500 mg twice daily)
Number of subjects: 800
Study: 9663357

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg once daily (n = 213)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg once daily (after dose doubling if SeDBP >= 90 mm Hg)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 432

Group type: COMPARATOR
Intervention: Losartan 50 mg once daily (n = 219)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Losartan 100 mg once daily (after dose doubling if SeDBP >= 90 mm Hg)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Losartan treatment
Number of subjects: 432
Study: 7523547

Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels measured using the immunometric assay (EIA Test Cyfra 21‐1)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels in patients with squamous cell tumors
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels in patients with adenocarcinomas
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels in patients with small cell lung cancer (SCLC)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels across different stages of lung cancer
Number of subjects: 584
Study: 3145820

Group type: EXPERIMENTAL
Intervention: Arginine (30 g i.v. over 30 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-dopa (500 mg orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHRH 1‐44 (200 micrograms i.v.)
Number of subjects: 0
Study: 30707877

Group type: EXPERIMENTAL
Intervention: Indirect energy measurement (metabolic vehicle) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Harris‐Benedict formula (HB formula) group
Number of subjects: 60
Study: 29437943

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 26910471

Group type: EXPERIMENTAL
Intervention: Docetaxel + Ramucirumab (n=43)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Docetaxel + Placebo (n=46)
Number of subjects: 89
Study: 24212915

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) infusion seven days before antiviral therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 85
Study: 23019296

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 2057

Group type: COMPARATOR
Intervention: Vaginal micronized progesterone tablets
Number of subjects: 2057
Study: 21142534

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 175

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 175
Study: 17545700

Group type: EXPERIMENTAL
Intervention: HAART plus systemic chemotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 33
Study: 15848684

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Monotherapy (combined data)
Number of subjects: 50
Study: 12200525

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP; 500 micro g twice daily, n=14)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 24
Study: 9833721

Group type: EXPERIMENTAL
Intervention: Mechanical aortic valve
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Homograft aortic valve
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 40
Study: 7986629

Group type: EXPERIMENTAL
Intervention: Oral hygiene (OH) twice a week until plaque was present at less than 20% of sites
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Root planing at 6 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral hygiene (OH) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sites with probing depths less than 4 mm at baseline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sites with probing depths of 6 mm or more
Number of subjects: 10
Study: 3190418

Group type: COMPARATOR
Intervention: 30 rpm cranking rate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 rpm cranking rate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 70 rpm cranking rate
Number of subjects: 10
Study: 29656405

Group type: EXPERIMENTAL
Intervention: Cellie Coping Kit for Children with Injury
Number of subjects: 61
Study: 7013054

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (600 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Indomethacin (75 mg daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid
Number of subjects: 50
Study: 31300845

Group type: EXPERIMENTAL
Intervention: ILM delamination (group 2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No ILM delamination (group 1)
Number of subjects: 32
Study: 28545757

Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment for Childhood Depression (FFT-CD)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Individual Supportive Psychotherapy (IP)
Number of subjects: 134
Study: 26298541

Group type: EXPERIMENTAL
Intervention: IRT plus MBI
Number of subjects: 44

Group type: COMPARATOR
Intervention: IRT
Number of subjects: 44
Study: 23824386

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB/β-TCP
Number of subjects: 434

Group type: COMPARATOR
Intervention: autograft
Number of subjects: 434
Study: 21470608

Group type: EXPERIMENTAL
Intervention: Real tDCS (2.0 mA for 20 minutes)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 21
Study: 18955513

Group type: EXPERIMENTAL
Intervention: Additional trunk exercises (10 hours of individual and supervised trunk exercises; 30 minutes, 4 times a week, for 5 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 33
Study: 17270679

Group type: EXPERIMENTAL
Intervention: TA‐assisted PPV
Number of subjects: 774

Group type: COMPARATOR
Intervention: Conventional PPV
Number of subjects: 774
Study: 16036078

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclical etidronate
Number of subjects: 0
Study: 11433085

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) at 0.8 ± 0.1 mg/kg body weight per day for 3.3 ± 0.6 years
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control period (before HCTZ therapy)
Number of subjects: 11
Study: 9773140

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen (i.v.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7880604

Group type: EXPERIMENTAL
Intervention: Doxorubicin 20 mg weekly
Number of subjects: 218

Group type: COMPARATOR
Intervention: Doxorubicin 20 mg weekly + high-dose medroxyprogesterone acetate (1000 mg daily)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate
Number of subjects: 218
Study: 2906479

Group type: EXPERIMENTAL
Intervention: Olsalazine, 1.5 g/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sulphasalazine, 3 g/day
Number of subjects: 41
Study: 31464089

Group type: EXPERIMENTAL
Intervention: Mean muscle attenuation (MA)
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Skeletal muscle index
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Worse performance status (ECOG 1/0), younger age, number of metastatic sites
Number of subjects: 761
Study: 31225673

Group type: EXPERIMENTAL
Intervention: Active treatment (combined nutraceutical containing bergamot extract, phytosterols, vitamin C, and chlorogenic acid)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-dose active treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active treatment (low-dose or high-dose)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29181557

Group type: EXPERIMENTAL
Intervention: Tailored multicomponent program implemented for 6 months followed by 6 months without the program
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Tailored multicomponent program
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 398
Study: 26342904

Group type: EXPERIMENTAL
Intervention: 2-session cognitive dissonance-based (DB) intervention (The PRIDE Body Project©)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 87
Study: 23629979

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (8 ml injected into the suprapatellar joint)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no PRP injection)
Number of subjects: 98
Study: 21556038

Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) 28-30 mg/kg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 19687349

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (untreated patients, n=7)
Number of subjects: 15
Study: 17045170

Group type: EXPERIMENTAL
Intervention: 2‐[18F]fluoro‐A‐85380 (2‐[18F]FA)
Number of subjects: 87